Primum non nocere (first, not to harm) and secundus, opinio vulnero (second, report the harm).
作者信息
Rivkees Scott A
机构信息
Yale Child Health Research Center, Yale University School of Medicine, New Haven, CT 06520, USA.
出版信息
Int J Pediatr Endocrinol. 2009;2009:303509. doi: 10.1155/2009/303509. Epub 2009 Mar 4.
Abstract
摘要
相似文献
1
Primum non nocere (first, not to harm) and secundus, opinio vulnero (second, report the harm).首要的是不伤害，其次是报告伤害。
Int J Pediatr Endocrinol. 2009;2009:303509. doi: 10.1155/2009/303509. Epub 2009 Mar 4.
2
Dealing with phthalates in medical devices: a case of primum non nocere (first do no harm)?医疗器械中邻苯二甲酸盐的处理：“首要之事，勿伤为先”之例？
Intensive Care Med. 2016 Apr;42(4):602-604. doi: 10.1007/s00134-016-4227-5. Epub 2016 Feb 3.
3
Primum non nocere: first do no harm: reponse to Phillida Bunkle.首要原则：不伤害：对菲利达·邦克尔的回应。
N Z Med J. 2018 Sep 21;131(1482):92-93.
4
A response to Primum non nocere: first do no harm.对“首要之务，不伤害”的回应：首先不要造成伤害。
N Z Med J. 2018 Jul 27;131(1479):91-92.
5
Primum non nocere: first do no harm.首要的是不伤害：先不造成伤害。
Med Times. 1957 Jul;85(7):729-31.
6
Primum non nocere-first, do no harm with bariatric surgery.首要的是不伤害——首先，减肥手术不要造成伤害。
Lancet Diabetes Endocrinol. 2021 Aug;9(8):476-477. doi: 10.1016/S2213-8587(21)00143-1. Epub 2021 Jul 1.
7
(first, to do no harm) in prostate biopsy.
Hong Kong Med J. 2019 Oct;25(5):344-345. doi: 10.12809/hkmj195088.
8
Primum non nocere - 'first do no harm'.首要的是不伤害——“首先不要造成伤害”。
Perfusion. 2020 May;35(4):277. doi: 10.1177/0267659120924914.
9
"Primum non nocere"--First do no harm.“首要之务，勿伤患者”—— 首先，不要造成伤害。
Hosp Pharm. 1976 Oct;11(10):392, 397.
10
Reply: Primum Non Nocere: First Do No Harm.回复：首要原则：切勿伤害，先不造成伤害。
J Am Coll Cardiol. 2015 Jul 28;66(4):492-3. doi: 10.1016/j.jacc.2015.05.043.
引用本文的文献
1
Characteristics and trends in adverse drug reactions in Ghana-evidence of spontaneous reports, 2005-2021.加纳药物不良反应的特征与趋势——2005年至2021年自发报告证据
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):657-672. doi: 10.1007/s00210-024-03302-5. Epub 2024 Jul 23.
2
Awareness, knowledge, and attitude toward adverse drug reaction (ADR) reporting among healthcare professionals in Ghana.加纳医疗保健专业人员对药品不良反应（ADR）报告的认知、知识和态度。
Ther Adv Drug Saf. 2022 Aug 6;13:20420986221116468. doi: 10.1177/20420986221116468. eCollection 2022.
3
Impact of an educational intervention on pharmacovigilance knowledge and attitudes among health professionals in a Nepal cancer hospital.教育干预对尼泊尔一家癌症医院卫生专业人员药物警戒知识和态度的影响。
BMC Med Educ. 2020 Jun 3;20(1):179. doi: 10.1186/s12909-020-02084-7.
4
Healthcare professionals' pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates.医疗保健专业人员的药物警戒知识、药品不良反应报告行为及决定报告率的因素。
J Drug Assess. 2019 Jan 5;8(1):13-20. doi: 10.1080/21556660.2019.1566137. eCollection 2019.
本文引用的文献
1
Update on the role of aromatase inhibitors in growth disorders.芳香化酶抑制剂在生长障碍中的作用的最新进展。
Horm Res. 2009 Jan;71 Suppl 1:57-63. doi: 10.1159/000178040. Epub 2009 Jan 21.
2
Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop.特发性身材矮小儿童诊断与治疗的共识声明：生长激素研究学会、劳森·威尔金斯儿科内分泌学会及欧洲儿科内分泌学会研讨会纪要
J Clin Endocrinol Metab. 2008 Nov;93(11):4210-7. doi: 10.1210/jc.2008-0509. Epub 2008 Sep 9.
3
Anaphylactic reaction to recombinant insulin-like growth factor-I.
J Pediatr Endocrinol Metab. 2008 Apr;21(4):381-4. doi: 10.1515/jpem.2008.21.4.381.
4
Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years.阿那曲唑可增加接受生长激素治疗的青春期矮小男孩的预测成年身高：一项为期一至三年的随机、安慰剂对照、多中心试验。
J Clin Endocrinol Metab. 2008 Mar;93(3):823-31. doi: 10.1210/jc.2007-1559. Epub 2007 Dec 28.
5
Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer.疾病机制：胰岛素样生长因子1受体途径的信号传导——癌症治疗前景
Nat Clin Pract Oncol. 2007 Oct;4(10):591-602. doi: 10.1038/ncponc0934.
6
The role of recombinant insulin-like growth factor I in the treatment of the short child.
Curr Opin Pediatr. 2007 Aug;19(4):458-64. doi: 10.1097/MOP.0b013e3282094126.
7
Post-marketing studies of drug efficacy: why?药物疗效的上市后研究：为何进行？
Am J Med. 1985 Mar;78(3):475-80. doi: 10.1016/0002-9343(85)90341-9.
Zotero 插件